News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FluimediX/MEMSflow ApS Closes Financing Round



9/20/2010 9:07:48 AM

TAASTRUP, Denmark--(BUSINESS WIRE)--FluimediX, a point-of-care diagnostic company, announced today that it has received funding for the continued development of the NanoCycler™, a diagnostic platform for the measurement of relevant genetic mutations in patients. The proceeds of this financing round will be dedicated to developing a diagnostic test for Warfarin™ metabolism. The investment round was led by SEED Capital Denmark, a leading early stage investor managing more than € 200 million in total assets. Existing shareholders also participated in the financing. The size of the round was not disclosed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES